MARKET

ATRS

ATRS

Antares Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.280
-0.090
-2.67%
After Hours: 3.280 0 0.00% 16:22 10/19 EDT
OPEN
3.370
PREV CLOSE
3.370
HIGH
3.470
LOW
3.270
VOLUME
803.04K
TURNOVER
--
52 WEEK HIGH
5.13
52 WEEK LOW
1.600
MARKET CAP
544.79M
P/E (TTM)
98.20
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Antares Pharma Inc (ATRS): Hedge Funds In Wait-and-See Mode
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
Insider Monkey · 10/12 23:28
Antares Is Finally Having A Long Overdue Upward Move
Since my last article in July, Antares has rallied over 20%, finally getting back to the lower end of where it was trading pre-COVID-19.This rally presumably has to do with the company returning to solid growth in Q2 and reporting a quarterly profit.Additionally, management made a small acquisition to put an additional product in Antares’ sales rep’s medicine bags when they visit urologists about Xyosted.Antares likely has more room to the upside as sales continue to grow.
Seekingalpha · 10/09 21:39
Antares Pharma (NASDAQ:ATRS) Shareholders Have Enjoyed A 85% Share Price Gain
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...
Simply Wall St. · 10/06 12:39
Antares Pharma Reports Exclusive License Deal With Ferring Pharma For Nocdurna In US
Antares Pharma, Inc. (NASDAQ:ATRS) (“the Company”), a pharmaceutical technology company, today announced that it entered into an exclusive license agreement with Ferring Pharmaceuticals
Benzinga · 10/01 13:03
Antares Pharma inks deal with Ferring Pharma for Nocdurna in U.S.
Antares Pharma (ATRS) has entered into an exclusive license agreement with Ferring Pharmaceuticals for the marketed product NOCDURNA (desmopressin acetate), which is indicated for the treatment of nocturia due to nocturnal
Seekingalpha · 10/01 12:56
Antares Pharma Enters Exclusive License Agreement With Ferring Pharmaceuticals for Nocdurna® in U.S.
Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that it entered into an exclusive license agreement with Ferring Pharmaceuticals (“Ferring”), a research-driven, specialty biopharmaceutical group, for the marketed product NOCDURNA® (desmopressin
GlobeNewswire · 10/01 12:46
Antares Pharma to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference
EWING, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference
GlobeNewswire · 09/08 13:00
These 4 Measures Indicate That Antares Pharma (NASDAQ:ATRS) Is Using Debt Reasonably Well
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Simply Wall St. · 09/06 15:14
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATRS. Analyze the recent business situations of Antares Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATRS stock price target is 6.25 with a high estimate of 8.00 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 212
Institutional Holdings: 86.33M
% Owned: 51.98%
Shares Outstanding: 166.09M
TypeInstitutionsShares
Increased
56
7.35M
New
35
4.17M
Decreased
45
6.68M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.37%
Healthcare Equipment & Supplies
-0.82%
Key Executives
Chairman/Independent Director
Leonard Jacob
President/Chief Executive Officer/Director
Robert Apple
Chief Financial Officer/Executive Vice President
Fred Powell
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Peter Graham
Independent Director
Thomas Garrity
Independent Director
Peter Greenleaf
Independent Director
Anton Gueth
Independent Director
Robert Roche
Independent Director
Karen Smith
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ATRS
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company's subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Antares Pharma Inc stock information, including NASDAQ:ATRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATRS stock methods without spending real money on the virtual paper trading platform.